| Literature DB >> 19672658 |
Yuichi Shimaoka1, Shunji Tajima, Fumio Fujimori, Cristiane Yamabayashi, Hiroshi Moriyama, Masaki Terada, Toshinori Takada, Eiichi Suzuki, Masashi Bando, Yukihiko Sugiyama, Ichiei Narita.
Abstract
Bleomycin (BLM)-induced lung injury consists of excessive inflammatory cell infiltration and fibrosis. IS-741 has been reported to be an anti-inflammatory drug through an inhibitory action on cell adhesion. In this study we investigated whether IS-741 could inhibit the progression of pulmonary fibrosis through inflammatory cell infiltration. Lung injury was induced in female C57BL/6 mice by intratracheal instillation of BLM. IS-741 was administered daily intraperitoneally. The hydroxyproline content and fluid content in the lung on Day 28 were significantly lower in the IS-741-treated mice. The histological degree of lung injury or fibrosis was reduced in IS-741-treated mice. Administration of IS-741 caused significant reduction in the absolute number of total cells, monocyte chemoattractant protein (MCP)-1, and cysteinyl leukotriene (cysLTs) levels in bronchoalveolar lavage fluid on Day 7. Furthermore, the hydroxyproline content was significantly lower in IS-741-treated mice even though IS-741 was started on Day 14 after BLM instillation. Treatment with IS-741 had an inhibitory effect on BLM-induced lung injury and fibrosis via the repression of MCP-1 or cysLTs in this murine experimental model.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19672658 DOI: 10.1007/s00408-009-9162-6
Source DB: PubMed Journal: Lung ISSN: 0341-2040 Impact factor: 2.584